Materials and methods
HNSCC specimens were dissociated into single cell suspensions, stained for cell surface markers and examined by fluorescence-activated cell sorting. A high-throughput screen for 340 cell surface markers was used to identify candidate biomarkers that could further enrich for TICs that were then functionally tested by performing in vivo limiting dilution assays. Total RNA was extracted from isolated TIC, non-TIC and CAF populations and real time PCR was performed.
Results
Three candidate biomarkers were identified and one marker, CD271, resides within the CD44+ fraction and further enriches for TIC activity. In well-differentiated tumors CD271 consistently localizes to the basal layer. Moreover, TIC, non-TIC and CAF populations contain distinct expression profiles.
Conclusions
We have identified CD271 as a biomarker that enriches for TIC activity. The distinguishing expression profiles for TICs, non-TICs, and CAFs are being further analyzed to determine essential signaling cascades that exist among these populations that could potentially be targeted for HNSCC treatment.
